Occult infection with hepatitis C virus (HCV) is defined as the presence of the HCV genome in either liver tissue or peripheral blood monocytes, despite constant negative results from tests for HCV RNA in serum. We investigated whether patients who maintained a sustained virologic response 12 weeks after therapy (SVR12) with directacting antiviral (DAA) agents for recurrent HCV infection after liver transplantation had occult HCV infections. We performed a prospective study of 134 patients with recurrent HCV infection after liver transplantation who were treated with DAAs, with or without ribavirin, from 2014 through 2016 (129 patients achieved an SVR12). In >10% of the patients who achieved SVR12 (n [ 14), serum levels of aminotransferases did not normalize during or after DAA therapy, or they normalized transiently but then increased sharply after DAA therapy. Of these 14 patients, 9 were assessed for occult HCV infection by reverse transcription quantitative polymerase chain reaction. This analysis revealed that 55% of these patients (n [ 5) had an occult infection, with the detection of negative strand viral genome, indicating viral replication. These findings indicate the presence of occult HCV infection in some patients with abnormal levels of serum aminotransferases, despite SVR12 to DAAs for HCV infection after liver transplantation.
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Keywords: Viral Hibernation; Treatment Outcome; Persistence; Limit of Detection. R ecurrent hepatitis C virus (HCV) infection after orthotopic liver transplantation (OLT) occurs in nearly all patients with viremia at the time of transplantation. 1 Direct-acting antiviral (DAA) treatment for recurrent HCV infection is highly indicated, as it can prevent graft failure.
1,2 At our institution, between the years 2014 and 2016, a total of 134 cases of recurrent HCV infections were treated with interferon-free DAA therapy with or without ribavirin. During treatment, serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) decreased rapidly, as did serum HCV-RNA in the majority of cases. Of those 134 cases, 129 patients achieved sustained virologic response 12 weeks after therapy (SVR12). The SVR12 patients were further subdivided into the following groups (Table 1) : biochemical remission, that is, serum aminotransferase values rapidly normalized during and after antiviral therapy, as did serum HCV-RNA; and biochemical nonresponders (BNRs), that is, serum aminotransferases either flared after the end of therapy or did not improve in parallel with HCV-RNA reduction. Based on these classifications, 14 patients were included in the BNRs. Given the deregulated immunity due to concomitant immunosuppressant, we hypothesized that the post-OLT liver is susceptible to develop occult HCV infection (OCI), which can contribute to abnormal aminotransferases seen after achieving SVR. Consequently, this study was designed to investigate the occurrence of OCI in these 14 cases of BNR. Of those 14 cases, 9 patients were enrolled upon obtaining informed consent under approved Institutional Review Board. The majority of the 9 cases of BNR demonstrated a transient improvement of serum aminotransferases during antiviral therapy, in parallel with the reduction of serum HCV-RNA. However, the transaminase values flared shortly after the end of antiviral treatment (subjects 1, 3À5, and 7À9) (Supplementary Figure 1) . The remaining subjects (subjects 2 and 6) exhibited either negligible improvement or worsening of serum transaminases (Supplementary Figure 1) . These enrolled 9 subjects underwent liver biopsies in order to seek an explanation for the ongoing hepatocellular injury (Supplementary Figure 1) . A portion of liver tissue, serum, and peripheral blood monocyte cells (PBMCs) were simultaneously collected and subjected to HCV-genome detection by a high-sensitive Taqman reverse transcription quantitative polymerase chain reaction assay developed in our laboratory (Supplementary Figure 2) . The results revealed that HCV-RNA was detected in a total of 5 subjects (55%): in the liver tissue of 4 subjects (44%), in the PBMCs of 2 subjects (22%), and in both in 1 subject ( Figure 1 ). A grossly identical result was obtained with Abbott Real-Time HCV viral load assay (Abbott Molecular, Des Plaines, IL) (Supplementary Figure 3) . Given that HCV is a single-stranded (þ) RNA virus, detection of the negative (À) strand genome serves as a signature of HCV replication. 3 Subsequently, the liver and PBMC samples that were positive for OCI were subjected to a strand-specific reverse transcription quantitative polymerase chain reaction for the quantification of (þ) and (À) strand HCV-genome. In general, the number of copies of (þ) strand is 1À3 logs greater than (À) strand in HCV replicating liver tissue due to a higher demand for (þ) strand as it is responsible for both viral protein translation and virion assembly. 4, 5 A similar trend was observed in our study using the liver tissue of subjects with active viremia or in the in vitro cultured HCV replicating cells ( Figure 1 ). Of great interest, the OCI had a greater proportion of (À) strand, thus the ratio between (þ) and (À) was much lower (Figure 1) . Accordingly, we speculate that the altered (þ)/(À) strand ratio may, at least in part, result in the interference of virion assembly/budding and the accumulation of HCV-RNA within the infected cells, while it sheds only trace amounts of virion into the serum.
The genotype of single nucleotide polymorphisms near interleukin 28B (IL28B) gene at rs12979860 (IL28B-genotype) is known to have a great influence on the outcomes of HCV infection. Thus, we tested whether the IL28B genotype is associated with the presence of OCI. The results revealed that all cases of OCI had the unfavorable genotype (TT), while the non-OCI subjects had either favorable (CC) or intermediate (CT) genotypes (Table 1 ). In addition, we did not find any correlation between OCI and the IL28B-genotype of the grafted liver, indicating that the TT genotype of the host and not the donor, might be a contributing factor to the development of OCI.
Next, we found that the histopathology of only 2 of the 4 cases of OCI in the liver were consistent with recurrent viral hepatitis C. In addition, 1 subject who had OCI in PBMC, but not in the liver, was reported to have recurrent viral hepatitis C (Supplementary Table 1 ). Furthermore, the histology of 1 subject who had OCI in the liver demonstrated features of acute cellular rejection and de novo autoimmune hepatitis. Taken together, we conclude that the histopathologic evaluation does not serve as a predictor for OCI.
We found the presence of OCI in 5 of 9 BNR subjects. At the same time, the causality of abnormal aminotransferases in the remaining cases remains elusive. Given concomitant immunosuppression, we speculate that other viral pathogens could be responsible for the abnormal AST/ALT and so we screened all samples for Parvoviridae, hepatitis B virus, hepatitis E virus, and herpesviruses. [6] [7] [8] [9] [10] The results found that 1 case of OCI was superinfected with Parvovirus B19 and adeno-associated virus 3, although the contribution of these pathogens to the abnormal AST/ALT remains unclear (Subject 1) (Supplementary Table 1 ). The occurrence of OCI in the immunocompetent population remains controversial, as it depends on the detection methods employed, ranging as high as 75%. [11] [12] [13] This is the first study to address the occurrence of OCI in the immunocompromised host and we found a relatively high incidence of OCI in post-OLT, DAA-treated subjects with abnormal aminotransferases. Of note, we did not find any correlation between the type and dose of immunosuppressant and the onset of OCI. In addition, it remains elusive whether OCI can be the causality of these abnormal aminotransferases. This question can also be extended to consider the implication of OCI in PBMC alone in hepatic inflammation, such as in subject 3 ( Figure 1 ). These are important questions because up to 30% of patients who are infected with HCV have normal serum aminotransferases. 14 In addition, a recent exciting observation with explanted livers treated with DAA suggested that the AST/ALT may not be a predictor of OCI. 15 To precisely address these questions, further investigations with normal AST/ALT subjects are necessary; however, the acquisition of such samples is hampered by the lack of justification for a liver biopsy. Another intriguing question that needs to be explored is the longitudinal outcomes of OCI and the identification of potential resistance-associated variants that may be associated with the development of OCI. In conclusion, our study results urge the utilization of tissue samplebased detection of HCV genome, at least for those with abnormal aminotransferases, especially with the unfavorable IL28B genotype. For the cases of OCI with sustained abnormal aminotransferases, an additional course of antiviral therapy can be considered to preserve the longevity of the graft due to possible inflammation caused by occult HCV infection.
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Supplementary Materials and Methods

Study Population
Post-OLT recurrent HCV infection patients were treated with interferon-free DAAs alone or combination with ribavirin at Keck Medical Center of University of Southern California during 2014À2016 (n ¼ 135). Of those who attained SVR (n ¼ 129), 115 patient achieved biochemical remission, while 14 patients continue to have abnormal aminotransferases and were classified as BNR. Nine BNRs were enrolled in this study. Figure 2A) . For strandspecific reverse transcription quantitative PCR, the complementary DNA synthesis from 25 ng total RNA was carried out with ThermoScript with 5 0 -tag sequencing (CATGGTGGCGAATAA) fused to either HCV-FWD primer or HCV-REV primer for (À) and (þ) strands, respectively. Then, the synthesized strand-specific complementary DNA was used for the Taqman quantitative PCR with the combination of tag-primer 5 0 -GGCCGTCATGGTGGCGAATAA-3 0 and either HCV-FWD or -REV primer. The sensitivity and the detection limit for the positive strand and negative strand (0.5 Â 10 3 and 0.5 Â 10 2 ) are shown in Supplementary Figure 2B and C) . In addition, the extracted RNA was used for the detection of HCV genome with Abbott Real-Time HCV assay utilizing Abbott HCV master mix (Abbott) with M2000rt PCR instruments.
Human Sample and Nucleic Acid Extraction
Interleukin 28B Genotyping
The SNPs at rs12979860 (IL28B genotype) were determined with the extracted DNA from both PBMC and the liver tissue with TaqMan Genotyping Master Mix (ThermoFisher) using the following primers and allele specific TaqMan probe:
Viral Serology
HBs antigen was assessed with Abbott ARCHITECT HBsAg Qualitative assay using ARCHITECT HBsAg Qualitative Reagent Kit (1P97) and ARCHITECT HBsAg Confirmatory V.1 Reagent Kit (9C94-25). AntiÀhepatitis B virus (HBV) core IgG was measured with ARCHITECT AntiHBc II Reagent Kit (8L44). Anti-HCV antibody was assessed ARCHITECT Anti-HCV Reagent Kit (6C37). Enzyme-linked immunosorbent assay for antiÀhepatitis E virus IgG and IgM were performed at Focus Diagnostic (Cypress, CA).
Histologic Evaluation
The needle liver biopsy samples were coded before the histologic evaluation. Two hepatopathologists independently assessed the histologic findings in a blind manner. The histologic findings were classified into 4 major categories: consistent or suggestive of recurrent viral hepatitis C and, if yes, evaluated for the degree of lobular inflammation; consistent or suggestive of acute cellular rejection; consistent or suggestive of de novo AIH; consistent or suggestive of other etiologies, and miscellaneous changes.
Plasmid. A plasmid encoding full-length HCV H77
genome, H/FL (LþI) (kindly provided by Dr Charles Rice, Rockefeller University) was used for PCR amplification with FWD primer 5 0 -ATCACTCCCCTGTGAGGAAC-3 0 and REV primer 5 0 -GTGCACGGTCTACGAGACCT-3 0 in order to obtain partial HCV genome encoding nt36-340 (AF009606.1). The amplicon was cloned into pMiniT using NEB PCR Cloning Kit (New England Biolabs, Ipswich, MA). Then, the partial HCV genome was digested with EcoRI for subcloning into pEF Myc/His Ver B. This resulted in the generation of pEF HCV H77 nt36-340 (þ) and (À) depending on the direction of the DNA fragment ligation to the upstream T7 sequence. The following plasmids were also used in this study as a standard; Kernow C1 P6 infectious clone (hepatitis E virus), pYT103c* (Parvovirus B19), pACG2 (AAV2), pAAVr3c3 (AAV3).
Viral genome detection of hepatitis B virus, hepatitis E virus, herpes simplex virus, cytomegalovirus, Epstein-Barr virus, Parvovirus B19, adeno-associated virus 2 and adeno-associated virus 3. Five hundred m liters (for HBV) or 200 mL (for cytomegalovirus, Epstein-Barr virus, and herpes simplex virus) serum was applied to MagnaPure 96 (Roche, Nutley, NJ) and the extracted DNA and spiked internal control material were eluted in 100 mL. In addition, the extracted DNA (37.5 ng for HBV or 50 ng for cytomegalovirus, Epstein-Barr virus, and herpes simplex virus) from PBMCs and liver tissue was also used for the detection of HBV, cytomegalovirus, Epstein-Barr virus, and herpes simplex virus with the conditions that were described previously. [1] [2] [3] [4] Quantitative results were obtained from standard curves generated from amplicon-containing plasmids. The cellular sample results were also normalized with b-globin quantities. RNA extracted from serum, PBMCs (25 ng), and liver tissue (25 ng) were also subjected to detection of hepatitis E virus using TaqMan Fast Virus 1-Step Master 0 UTR (nt36À340) with tagged strand-specific primer was used for the second step RT-qPCR. The positive correlation with a correlation coefficient (R 2 ) is described within the graph. Gray dots connected with dotted line represent threshold cycle (CT) value of serially diluted partial HCV genome. NTC, non-template control (molecular grade water). Three individual liver tissue samples of non-HCVÀrelated liver disease are used as negative control (uninfected).
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